FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 74 filers reported holding FATE THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $147 | -99.9% | 14,594 | +15.2% | 0.02% | -26.9% |
| Q3 2022 | $284,000 | -70.7% | 12,673 | +7.8% | 0.03% | -62.3% |
| Q1 2021 | $970,000 | +502.5% | 11,759 | -28.8% | 0.07% | +666.7% |
| Q1 2018 | $161,000 | +43.8% | 16,521 | -9.5% | 0.01% | +50.0% |
| Q4 2017 | $112,000 | +53.4% | 18,251 | -1.3% | 0.01% | +50.0% |
| Q3 2017 | $73,000 | – | 18,493 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |